Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 740.15

-1.2%

10:02 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (42)	1/13/1997 10:34:00 PM
From: cl	of 3560

got this from today's Mercury Mail, see the optimism? * EVEREN Securities reduced its earnings estimate for AMGEN INC's fiscal 1999 earnings to $3.09 from $3.10 a share and its estimate for 2000 to $3.69 from $3.72 a share. EVEREN analyst Albert Rauch cited the results of recent tests of Amgen's brain-derived neurotropic factor (BDNF), which Amgen said did not show efficacy in the treatment of amyotropic lateral sclerosis (ALS). Amgen is discontinuing development of subcutaneously administered BDNF for ALS, EVEREN said. Rauch said he remains optimistic about the develpment of intrathecal (spinal) administration of BDNF, since a majority of the neurons degenerated by ALS are found in the spinal cord. (Reuters 05:55 PM ET 01/13/97) Chuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next